147 related articles for article (PubMed ID: 22790015)
1. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
McMillen BD; Aponte MM; Liu Z; Helenowski IB; Scholtens DM; Buttin BM; Wei JJ
Mod Pathol; 2012 Dec; 25(12):1644-53. PubMed ID: 22790015
[TBL] [Abstract][Full Text] [Related]
2. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.
Mahajan A; Liu Z; Gellert L; Zou X; Yang G; Lee P; Yang X; Wei JJ
Mod Pathol; 2010 May; 23(5):673-81. PubMed ID: 20228781
[TBL] [Abstract][Full Text] [Related]
3. [Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers].
Yang J; Zhang Q; Dong JQ; Chang XH; He XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):749-54. PubMed ID: 23073586
[TBL] [Abstract][Full Text] [Related]
4. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
8. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
Liu Z; Liu J; Segura MF; Shao C; Lee P; Gong Y; Hernando E; Wei JJ
J Pathol; 2012 Oct; 228(2):204-15. PubMed ID: 22322863
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
[TBL] [Abstract][Full Text] [Related]
10. Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice.
Xu X; Ayub B; Liu Z; Serna VA; Qiang W; Liu Y; Hernando E; Zabludoff S; Kurita T; Kong B; Wei JJ
Mol Cancer Ther; 2014 Jul; 13(7):1729-39. PubMed ID: 24825857
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
12. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
13. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.
Wu J; Liu Z; Shao C; Gong Y; Hernando E; Lee P; Narita M; Muller W; Liu J; Wei JJ
Cancer Res; 2011 Jan; 71(2):349-59. PubMed ID: 21224353
[TBL] [Abstract][Full Text] [Related]
14. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
Wu J; Lai M; Shao C; Wang J; Wei JJ
Oncol Rep; 2015 Sep; 34(3):1494-502. PubMed ID: 26165228
[TBL] [Abstract][Full Text] [Related]
15. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
16. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
17. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
19. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
[TBL] [Abstract][Full Text] [Related]
20. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
